CTLA4 and melanoma: These data highlight the urgent need for identification of baseline biomarkers of response to identify patients who should be treated with mono versus combination ICB, or novel treatment combinations for patients deemed less likely to respond to the current most effective combination therapy in melanoma; ipilimumab (anti-CTLA-4) + nivolumab (anti-PD-1).